NMT1 and melanoma: First generation NMT-inhibitors such as Tris dibenzylidenacetone dipalladium (Tris DBA) inhibited NMT1 with IC50 = 1.0 μM in vitro, blocked MAPK and Akt signaling in cells, and demonstrated anti-tumor activity in a mouse melanoma model [38].